Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Fineline Cube Jul 30, 2026
Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Fineline Cube Jul 30, 2026
Company Drug

MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting

Fineline Cube Jun 3, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...

Company Deals

Hanx Bio Files for Hong Kong IPO with ICBC International as Sole Sponsor

Fineline Cube Jun 3, 2025

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. this week made another initial public offering (IPO) filing...

Company Drug

R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease

Fineline Cube Jun 3, 2025

Sichuan R&B Biotech, a China-based biotech firm, announced receiving clinical approval from the US Food...

Company Drug

GSK’s Linerixibat NDA Accepted by FDA for Cholestatic Pruritus in PBC Patients

Fineline Cube Jun 3, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that the New Drug Application (NDA) for...

Company Deals

Shanghai Ark Bio and Partex Collaborate on ATR Inhibitor AK0658 Development

Fineline Cube Jun 3, 2025

China’s Shanghai Ark Biopharmaceutical Co., Ltd. has entered into a new cooperation agreement with Germany-based...

Company Drug

Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan

Fineline Cube Jun 3, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) this week filed a marketing application with Japan’s...

Company Deals

MicroPort CardioFlow to Acquire 49% Stake in La Ronda for RMB 171 Million

Fineline Cube Jun 3, 2025

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company

MSD Appoints Kyle Tattle as President of China Operations

Fineline Cube May 30, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced leadership changes in its China and...

Company Drug

Zelgen’s Jaktinib Receives NMPA Approval for Myelofibrosis Treatment

Fineline Cube May 30, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received marketing approval from...

Others

MSD and Daiichi Sankyo Withdraw US Filing for Patritumab Deruxtecan in EGFR-Mutated NSCLC

Fineline Cube May 30, 2025

Partners Merck, Sharp & Dohme (MSD; NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced the...

Company Drug

Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals

Fineline Cube May 30, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the receipt of marketing...

Company Deals

CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals

Fineline Cube May 30, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...

Company Medical Device

Acotec Scientific’s E-Peridge Balloon Catheter Approved by China’s NMPA

Fineline Cube May 30, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Company Drug

Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013

Fineline Cube May 30, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received separate marketing...

Company Drug

NMPA Approves Mabwell’s 8MW0511 for Febrile Neutropenia Prevention

Fineline Cube May 30, 2025

China’s National Medical Products Administration (NMPA) has approved Mabwell (Shanghai) Bioscience Co., Ltd’s (SHA: 688062)...

Company Drug

Hinova’s Deutenzalutamide Approved for Metastatic Prostate Cancer in China

Fineline Cube May 30, 2025

Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) announced that the New Drug Application (NDA) for...

Company Drug

Sino Biopharmaceutical’s TQB2868 Shows Strong Results in Phase II Pancreatic Cancer Trial

Fineline Cube May 30, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented data from its Phase II clinical trial (TQB2868-ALTN-II-01)...

Company Drug

Hansoh Pharma Gains NMPA Clinical Approvals for HS-10510, HS-10542, and HS-20118

Fineline Cube May 30, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received separate clinical...

Company Drug

Genor Biopharma Gains NMPA Approval for CDK4/6 Inhibitor Lerociclib in China

Fineline Cube May 30, 2025

China’s Genor Biopharma Co., Ltd (HKG: 6998) announced that it has received marketing clearance from...

Company Deals

Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development

Fineline Cube May 30, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...

Posts pagination

1 … 187 188 189 … 701

Recent updates

  • Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease
  • Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements
  • Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression
  • Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares
  • CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Company Drug

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.